Characterization of an anti-Trop-2-SN-38 antibody-drug conjugate (IMMU-132) with potent activity against solid cancers.

作者
David M. Goldenberg,Edmund A. Rossi,Serengulam V. Govindan,Thomas M. Cardillo,William J. McBride,Maria B. Zalath,Gaby Terracina,Preeti Trisal,Robert M. Sharkey
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:32 (15_suppl): 3107-3107 被引量:5
标识
DOI:10.1200/jco.2014.32.15_suppl.3107
摘要

3107 Background: IMMU-132 is an antibody-drug conjugate (ADC) made from a humanized anti-Trop-2 mAb (hRS7) coupled through a linker to SN-38, the active metabolite of CPT-11. Trop-2 is found in a wide range of tumor, including gastric, pancreatic, triple-negative breast (TNBC), colonic, prostate, and lung. Current Phase I/II clinical trials confirm the anticancer activity of IMMU-132 in cancers expressing Trop-2. The current studies further characterize IMMU-132 in terms of conjugation, mechanism of action (MoA), and efficacy. Methods: SN-38 conjugation to hRS7 was analyzed by HIC, LC-MS, and HPLC. MoA was assessed by comparisons in binding, ADCC, and pro-apoptotic signaling pathways. Efficacy studies were performed in mice bearing human tumor xenografts. Results: IMMU-132 has a drug to antibody ratio of 7.6, <1% aggregation, and no loss in binding to cells or to a Trop-2 chip (cells: KD = 0.63 ± 0.26 nM v 0.54 ± 0.17 nM; BIACore: 0.26 ± 0.14 v 0.51 ± 0.04 nM, IMMU-132 and hRS7, respectively). Linkage chemistry should preserve the active lactone ring form; initial in vivo data suggest that conjugated SN-38 may not be glucuronidated until released. IMMU-132 retains binding to the neonatal receptor, but lost 65% of ADCC activity. Free SN-38 and IMMU-132 mediated the same signaling pathways in cells, with p21WAF1/Cip1 up-regulation, cleavage of caspase 3 and 9, and poly-ADP-ribose polymerase cleavage. IMMU-132 treatment of gastric cancer xenografts (17.5 mg/kg; 2xwk x 4wks) result in significant anti-tumor effects compared to non-specific control ADC (P<0.0001). In tumors not typically treated with irinotecan as a single agent (pancreatic and TNBC), IMMU-132 provided significant tumor growth inhibition. Mice with a TNBC xenograft treated with 12.5 mg/kg IMMU-132 (q4dx4) resulted in 7/8 mice alive at study conclusion (day 105) v only 1/9 in saline-control group (P=0.001). Tumor regressions occur in mice bearing aggressive pancreatic tumor xenografts (untreated median survival = 11 d) when clinically relevant doses of IMMU-132 is given (HED=8 mg/kg; P=0.0003). Conclusions: Conjugation of SN-38 to hRS7 results in a potent ADC that retains characteristics of both the antibody and the drug.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yeahCZY完成签到,获得积分10
刚刚
刚刚
lmh发布了新的文献求助10
刚刚
Ren的应助被科研通管家采纳,获得10
刚刚
yang发布了新的文献求助10
刚刚
田様的应助被柚子采纳,获得10
刚刚
刚刚
华仔的应助被科研通管家采纳,获得10
刚刚
学术雷锋的应助被科研通管家采纳,获得10
刚刚
帅气东蒽完成签到,获得积分10
刚刚
吕狗蛋完成签到,获得积分10
刚刚
CipherSage的应助被科研通管家采纳,获得10
1秒前
Ava的应助被lmg采纳,获得10
1秒前
闪闪的灵的应助被科研通管家采纳,获得200
1秒前
1秒前
1秒前
1秒前
取名鬼才发布了新的文献求助10
1秒前
充电宝的应助被科研通管家采纳,获得30
1秒前
1秒前
bkagyin的应助被科研通管家采纳,获得10
1秒前
1秒前
思源的应助被科研通管家采纳,获得10
1秒前
1秒前
xu发布了新的文献求助10
2秒前
2秒前
ZZB完成签到,获得积分10
2秒前
无极微光的应助被李腾达采纳,获得20
2秒前
王小果发布了新的文献求助10
2秒前
chen的应助被耀眼采纳,获得10
3秒前
fortuna发布了新的文献求助10
3秒前
3秒前
的的完成签到,获得积分10
3秒前
SciGPT的应助被幸运鹅采纳,获得10
3秒前
eric6717完成签到,获得积分10
3秒前
3秒前
局外人发布了新的文献求助10
4秒前
4秒前
Pheonix1998完成签到,获得积分10
4秒前
Jasper的应助被HenryRen采纳,获得10
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159790
求助须知:如何正确求助?哪些是违规求助? 9555224
关于积分的说明 21726021
捐赠科研通 7749765
什么是DOI,文献DOI怎么找? 3427296
关于科研通互助平台的介绍 2552375
邀请新用户注册赠送积分活动 2471654